51
|
Solomon B, Soria J, Blackhall F, Shaw A, Camidge D, Kim D, Mok T, Fernandez-Banet J, Kan Z, Li S, Liu Y, Ho S. P1.01-016 Next-Generation Sequencing Shows Mechanisms of Intrinsic Resistance in ALK-Positive NSCLC Patients Treated with Crizotinib. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
52
|
Solomon B, Shaw A, Ou S, Besse B, Felip E, Bauer T, Soo R, Bearz A, Lin C, Clancy J, Abbattista A, Thurm H, Peltz G, Masters E, Martini J, James L, Seto T. OA 05.06 Phase 2 Study of Lorlatinib in Patients with Advanced ALK+/ROS1+ Non-Small-Cell Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.351] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
53
|
Shaw A, Kim D, Solomon B, Felip E, Riely G, Schuler M, Tan D, Chow L, Camidge D, Urban P, Ortmann C, Malet I, Mehra R. P1.01-012 Ceritinib in Anaplastic Lymphoma Kinase (ALK)+ NSCLC Patients Pretreated With Only Crizotinib: ASCEND-1 Subgroup Analysis. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
54
|
Drilon A, Clark J, Weiss J, Ou S, Camidge D, Solomon B, Otterson G, Villaruz L, Riely G, Heist R, Shapiro G, Murphy D, Liu Y, Wang S, Usari T, Wilner K, Paik P. OA 12.06 Plasma Genomic Profiling and Outcomes of Patients with MET Exon 14-Altered NSCLCs Treated with Crizotinib on PROFILE 1001. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
55
|
Gamell C, Gulati T, Solomon B, Haupt S, Haupt Y. Uncovering a novel pathway for p16 silencing: Therapeutic implications for lung cancer. Mol Cell Oncol 2017; 4:e1299273. [PMID: 29057301 DOI: 10.1080/23723556.2017.1299273] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2017] [Revised: 02/19/2017] [Accepted: 02/20/2017] [Indexed: 10/20/2022]
Abstract
A key step during onset of most cases of non-small cell lung cancer (NSCLC) is the loss of the tumor suppressor p16INK4a (best known as p16), commonly due to promoter hypermethylation. We recently reported a novel regulatory pathway involving E6-associated protein and cell division control protein 6, which provides a methylation-independent mechanism for p16 silencing in patients with a particularly aggressive form of NSCLC.
Collapse
|
56
|
Piotrowska Z, Liu E, Varga A, Thakur M, Narayanan V, Liu S, Neal J, Spiegel M, Solomon B, Yu H, Ou SH, Papadimitrakopoulou V, Gadgeel S, Camidge D, Soria JC, Wakelee H, Goldman J, Kopani K, Rolfe L, Sequist L. Rociletinib-associated cataracts in EGFR-mutant NSCLC. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.39] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
57
|
Solomon B, Soria JC. The continuum of care for ALK-positive NSCLC: from diagnosis to new treatment options – an overview. Ann Oncol 2016; 27 Suppl 3:iii1-iii3. [DOI: 10.1093/annonc/mdw300] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
|
58
|
Alexander M, Wolfe R, Ball D, Manser R, McManus M, Riedel B, Solomon B, Westerman D, Burbury K. OC-05 - D-Dimer, fibrinogen and TEG-MA predict thromboembolism in non-small cell lung cancer – interim results from a prospective cohort study. Thromb Res 2016; 140 Suppl 1:S170. [DOI: 10.1016/s0049-3848(16)30122-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
59
|
Williams CB, Krie A, De P, Dey N, Klein J, Williams KA, Hoogeveen M, Solomon B, Leyland-Jones B. Abstract P5-16-01: Implementation of routine genomic and proteomic profiling of metastatic breast cancer patients in a community cancer center. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-16-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The optimal treatment strategy for patients with metastatic breast cancer (MBC) is currently unknown. Resistance to standard therapies, including anthracyclines and taxanes, limit the number of treatment options in many patients to a small number of non-cross resistant regimens. Rational combination approaches that are selected based upon genomic and proteomic analysis represents a possible advance that warrants extensive exploration.
Methods: Single center analysis of 77 consecutive metastatic breast cancer patients seen over a 12 month period (June 2014 through May 2015). All patients were referred for sequencing and the metastatic disease was rebiopsied. All samples were sent for standard pathologic, genomic (FoundationOne), and proteomic (TheraLink) analysis.
Results: Genomic and proteomic analysis yielded actionable targets in a majority of cases (89%). The most common pathways involved were the following: PI3K/Akt/mTOR (73%), MAPK (46%), ErbB (36%), FGFR (25%), and Jak/STAT (11%). Over 100 unique molecular aberrations were identified in 40 evaluable patients. Current outcomes are summarized in Table 1. The overall response rate was 45%, with another 43% of patients with stable disease. Average number of prior therapies was over 4, with a range of 1-11.
Table 1ER+/HER2-CR = 3PR = 8SD = 15PD = 2NE = 20ER+/HER2+CR = 2PR = 2SD = 1PD = 0NE = 9ER-/HER2+CR = 0PR = 1SD = 1PD = 1NE = 2Triple NegativeCR = 0PR = 2SD = 0PD = 2NE = 6Total evaluable patients = 40Overall CR = 13%Overall PR = 33%Overall SD = 43%Overall PD = 13%Total Not Evaluable = 37 pts (48%)Overall Response Rate (ORR) = 45% CR = complete response PR = partial response SD = stable disease PD = progressive disease NE = not evaluable
Conclusion: Since current literature suggests that an overall response rate of approximately 10% or less is expected for patients that have received greater than 4 previous lines of therapy, the ORR seen in this analysis is quite remarkable. Most patients in this analysis were treated with FDA approved drugs off label, which provided additional challenges and was the primary reason that many patients were not evaluable. Patients were only evaluable if they received the recommended therapy and were measured for outcome. Our initial data provides growing evidence that it is critical to incorporate genomic and proteomic analysis (preferably as early as possible in the disease course) to allow for the best chance of disease response.
Citation Format: Williams CB, Krie A, De P, Dey N, Klein J, Williams KA, Hoogeveen M, Solomon B, Leyland-Jones B. Implementation of routine genomic and proteomic profiling of metastatic breast cancer patients in a community cancer center. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-16-01.
Collapse
|
60
|
Weeden CE, Solomon B, Asselin-Labat ML. FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. Cell Death Discov 2015; 1:15049. [PMID: 27551478 PMCID: PMC4979434 DOI: 10.1038/cddiscovery.2015.49] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2015] [Accepted: 09/17/2015] [Indexed: 12/29/2022] Open
Abstract
Although the incidence of lung cancer has decreased due to the reduction of tobacco use, lung cancer remains the leading cause of cancer-related death. Lung squamous cell carcinoma represents 30% of lung cancers and only recently have possible drug-targetable mutations been identified in this disease, including fibroblast growth factor receptor 1 (FGFR1) gene amplification and genetic alterations in the phosphoinositide-3 kinase pathway. These discoveries have generated a great interest in the clinic and the initiation of clinical trials using FGFR tyrosine kinase inhibitors to treat FGFR-altered lung cancers. However, preliminary results from these studies have shown that not all patients respond to therapy. Here we review current unresolved questions on the selection of patients for their recruitment in FGFR tyrosine kinase inhibitor trials, how FGFR inhibitors could be combined with other targeted therapies or immunotherapies to improve patient outcome, and how the current preclinical models can help address these questions.
Collapse
|
61
|
Dor-On E, Schneider D, Solomon B. Intranasal administration of Ff bacteriophages towards cancer therapy. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv514.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
62
|
Solomon B, Rabinovich-Nikitin I. Rehabilitation of blood-spinal cord-barrier toward amyotrophic lateral sclerosis therapy. J Neurol Sci 2015. [DOI: 10.1016/j.jns.2015.08.204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
63
|
Williams C, Rojas L, Starks D, Williams K, Solomon B, Klein J, Dey N, De P, Leyland-Jones B. 2753 Feasibility of implementing routine genomic and proteomic profiling for advanced GYN malignancies. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31519-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
64
|
Solomon B, Wakelee H, Sequist L, Gadgeel S, Soria J, Goldman J, Yu H, Camidge D, Papadimitrakopoulou V, Matheny S, Despain D, Besse B. 3104 Rociletinib treatment and outcomes in non-small cell lung cancer (NSCLC) patients with negative central testing for T790M. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31745-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
65
|
Soria J, Goldman J, Wakelee H, Gadgeel S, Camidge D, Solomon B, Yu H, Oxnard G, Ou S, Papadimitrakopoulou V, Perol M, Reckamp K, Varga A, Dziadziuszko R, Chouaid C, Cortot A, Do P, Moro-Sibilot D, Poudenx M, Sequist L. 3105 Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31746-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
66
|
Gadgeel S, Soria J, Goldman J, Wakelee H, Camidge D, Yu H, Varga A, Solomon B, Oxnard G, Ou S, Papadimitrakopoulou V, Liu S, Reckamp K, Spira A, Piotrowska Z, Despain D, Karlovich C, Yurasov S, Sequist L. 3088 Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31729-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
67
|
Varga A, Camidge D, Sequist L, Wakelee H, Ou S, Goldman J, Papadimitrakopoulou V, Gadgeel S, Mekhail T, Oxnard G, Socinski M, Solomon B, Yu H, Matheny S, Despain D, Soria J. 3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31654-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
68
|
Young RJ, Urban D, Angel C, Corry J, Lyons B, Vallance N, Kleid S, Iseli TA, Solomon B, Rischin D. Frequency and prognostic significance of p16(INK4A) protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma. Br J Cancer 2015; 112:1098-104. [PMID: 25688737 PMCID: PMC4366899 DOI: 10.1038/bjc.2015.59] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2014] [Revised: 11/18/2014] [Accepted: 01/19/2015] [Indexed: 12/30/2022] Open
Abstract
Background: Human papillomavirus (HPV) infection is a powerful prognostic biomarker in a subset of head and neck squamous cell carcinomas, specifically oropharyngeal cancers. However, the role of HPV in non-oropharyngeal sites, such as the larynx, remains unconfirmed. Methods: We evaluated a cohort of 324 laryngeal squamous cell carcinoma (LSCC) patients for the expression of p16INK4A (p16) protein by immunohistochemistry (IHC) and for high-risk HPV E6 and E7 mRNA transcripts by RNA in situ hybridisation (ISH). p16 expression and HPV status were correlated with clinicopathological features and outcomes. Results: Of 307 patients assessable for p16 IHC, 20 (6.5%) were p16 positive. Females and node-positive patients were more likely to be p16 positive (P<0.05). There were no other significant clinical or demographic differences between p16-positive and -negative cases. There was no difference in overall survival (OS) between p16-positive and -negative patients with 2-year survival of 79% in each group (HR=0.83, 95% CI 0.36–1.89, P=0.65). There was no statistically significant difference in failure-free survival (FFS) with 2-year FFS of 79% and 66% for p16-positive and -negative patients, respectively (HR=0.60, 95% CI 0.26–1.36, P=0.22). Only seven cases were found to be HPV RNA ISH positive, all of which were p16 IHC positive. There was no statistically significant difference in OS between patients with HPV RNA ISH-positive tumours compared with -negative tumours with 2-year survival of 86% and 71%, respectively (HR=0.76, 95% CI 0.23–2.5, P=0.65). The 2-year FFS was 86% and 59%, respectively (HR=0.62, 95% CI 0.19–2.03, P=0.43). Conclusions: p16 overexpression is infrequent in LSCC and the proportion of cases with high-risk HPV transcripts is even lower. There are no statistically significant correlations between p16 IHC or HPV RNA ISH status and OS or disease outcomes.
Collapse
|
69
|
De P, Williams C, Krie A, Solomon B, Sun Y, Williams K, Klein J, Carlson J, Dey N, Leyland-Jones B. P049 Genomic landscape of the PI3K pathway and cell-cycle pathway in ER+ BC: a treatment strategy. Breast 2015. [DOI: 10.1016/s0960-9776(15)70099-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
70
|
Dey N, Williams C, Krie A, Solomon B, Sun Y, Williams K, Klein J, Carlson J, De P, Leyland-Jones B. P024 Navigating genomic landscape: PI3KSIGNALING algorithm for rational combination in precision medicine. Breast 2015. [DOI: 10.1016/s0960-9776(15)70074-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
71
|
Williams C, De P, Dey N, Williams K, Klein J, Young B, Willis S, Solomon B, Krie A, Leyland-Jones B. P068 Sequencing to identify potential targets of resistance to primary therapy. Breast 2015. [DOI: 10.1016/s0960-9776(15)70118-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
72
|
Lim A, Wong N, Pidsley R, Zontenko E, Corry J, Dobrovic A, Solomon B, Rischin D, Clark S. PO-097: Genome-scale methylation assessment did not identify prognostic biomarkers in oral tongue carcinomas. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)34857-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
73
|
Shaw A, Ou S, Bang Y, Camidge R, Solomon B, Salgia R, Riely G, Varella-Garcia M, Shapiro G, Costa D, Doebele R, Le L, Zheng Z, Stephenson P, Shreeve S, Tye L, Christensen J, Wilner K, Clark J, Iafrate A. Clinical Activity of Crizotinib in Ros1-Rearranged Non-Small Cell Lung Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.78] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
74
|
Felip E, Kim D, Mehra R, Tan D, Chow L, Camidge D, Vansteenkiste J, Sharma S, De Pas T, Riely G, Solomon B, Wolf J, Thomas M, Schuler M, Lui G, Santoro A, Geraldes M, Boral A, Yovine A, Shaw A. Efficacy and Safety of Ceritinib in Patients (Pts) with Advanced Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): an Update of Ascend-1. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.74] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
75
|
Blackhall F, Felip E, Cappuzzo F, Kim D, Wu Y, Solomon B, Nakagawa K, Mekhail T, Paolini J, Usari T, Iyer S, Reisman A, Wilner K, Tursi J, Mok T. Impact of Crizotinib on Patient-Reported Symptoms and Global Quality of Life (Qol) Compared with Platinum Based Chemotherapy in Phase III Study of Treatment Naïve Advanced Alk-Positive Non-Small Cell Lung Cancer (Nsclc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|